CAR T-Cell Therapy Market Growth, Size, Trends Analysis- By Drug Type, By Indication, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

CAR T-Cell Therapy Market Introduction and Overview

According to SPER Market Research, 'Global CAR T-Cell Therapy Market Size- By Drug Type, By Indication, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' states that the Global CAR T-Cell Therapy Market is estimated to reach USD 46.23 billion by 2033 with a CAGR of 28.78%.

One of the most innovative methods for treating cancer is CAR T-cell therapy. This novel immunotherapy fights cancer by utilizing the patient's immune system. For patients who have not responded to traditional treatments for a variety of hematologic malignancies, such as various types of leukemia and lymphoma, CAR T-cell therapy has demonstrated exceptional potential as a game-changing therapeutic alternative.

In 2020, the COVID-19 pandemic slowed the development of CAR-T cell therapy. The poor diagnostic rate of blood cancer was mostly caused by a number of issues that beset the healthcare system throughout the epidemic. First, the pandemic reduced the frequency of routine medical checks and screenings because many clinics and hospitals delayed unnecessary testing and visits in an effort to reduce the risk of COVID-19 virus transmission.

Scope of the report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Drug Type, By Indication, By End User

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Autolus Therapeutics, Bluebird Bio, Inc., Bristol-Myers Squibb, Caribou Biosciences, Inc., Cellectis, Celgene Corporation, Gilead Sciences, Inc., Intellia Therapeutics, Juno Therapeutics, Inc., Inc., Miltenyi Biotech, Novartis AG, Pfizer, Inc.

CAR T-Cell Therapy Market Segmentation:

By Drug Type: Based on the Drug Type, Global CAR T-Cell Therapy Market is segmented as; Axicabtage Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others.

By Indication: Based on the Indication, Global CAR T-Cell Therapy Market is segmented as; Lymphoma, Acute Lymphocytic Leukemia, Others.

By End User: Based on the End User, Global CAR T-Cell Therapy Market is segmented as; Hospitals, Cancer Treatment Centers.

By Region: This research also include data for North America, Europe, Asia-Pacific Middle East & Africa and South America.

Product Code: PHAR2414

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Global CAR T-Cell Therapy Market.

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global CAR T-Cell Therapy Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global CAR T-Cell Therapy Market

7. Global CAR T-Cell Therapy Market, By Drug Type (USD Million) 2020-2033

7.1. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Drug Type, 2020-2026
7.2. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Drug Type, 2027-2033
7.3. Axicabtagene Ciloleucel
7.4. Tisagenlecleucel
7.5. Brexucabtagene Autoleucel
7.6. Others

8. Global CAR T-Cell Therapy Market, By Indication (USD Million) 2020-2033

8.1. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Indication, 2020-2026
8.2. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Indication, 2027-2033
8.3. Lymphoma
8.4. Acute Lymphocytic Leukemia
8.5. Others

9. Global CAR T-Cell Therapy Market, By End User (USD Million) 2020-2033

9.1. Global CAR T-Cell Therapy Market Size, Share and Forecast, By End User, 2020-2026
9.2. Global CAR T-Cell Therapy Market Size, Share and Forecast, By End User, 2027-2033
9.3. Hospitals
9.4. Cancer Treatment Centers

10. Global CAR T-Cell Therapy Market Forecast, 2020-2033 (USD Million)

10.1. Global CAR T-Cell Therapy Market Size and Market Share

11. Global CAR T-Cell Therapy Market, By Region, 2020-2033 (USD Million)

11.1. Global CAR T-Cell Therapy Market Size and Market Share By Region (2020-2026)
11.2. Global CAR T-Cell Therapy Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
- 11.3.1. Australia
- 11.3.2. China
- 11.3.3. India
- 11.3.4. Japan
- 11.3.5. South Korea
- 11.3.6. Rest of Asia-Pacific
11.4. Europe
- 11.4.1. France
- 11.4.2. Germany
- 11.4.3. Italy
- 11.4.4. Spain
- 11.4.5. United Kingdom
- 11.4.6. Rest of Europe
11.5. Middle East and Africa
- 11.5.1. Kingdom of Saudi Arabia
- 11.5.2. United Arab Emirates
- 11.5.3. Qatar
- 11.5.4. South Africa
- 11.5.5. Egypt
- 11.5.6. Morocco
- 11.5.7. Nigeria
- 11.5.8. Rest of Middle-East and Africa
11.6. North America
- 11.6.1. Canada
- 11.6.2. Mexico
- 11.6.3. United States
11.7. Latin America
- 11.7.1. Argentina
- 11.7.2. Brazil
- 11.7.3. Rest of Latin America

12. Company Profile

12.1. Autolus Therapeutics
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Bluebird Bio, Inc.
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Bristol-Myers Squibb
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. Caribou Biosciences, Inc.
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. Cellectis
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Celgene Corporation
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Celyad Oncology
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Cartesian Therapeutics, Inc.
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Gilead Sciences, Inc. (Kite Pharma Inc.)
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Intellia Therapeutics
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Juno Therapeutics, Inc.
- 12.11.1. Company details
- 12.11.2. Financial outlook
- 12.11.3. Product summary
- 12.11.4. Recent developments
12.12. Merck & Co., Inc.
- 12.12.1. Company details
- 12.12.2. Financial outlook
- 12.12.3. Product summary
- 12.12.4. Recent developments
12.13. Miltenyi Biotech
- 12.13.1. Company details
- 12.13.2. Financial outlook
- 12.13.3. Product summary
- 12.13.4. Recent developments
12.14. Novartis AG
- 12.14.1. Company details
- 12.14.2. Financial outlook
- 12.14.3. Product summary
- 12.14.4. Recent developments
12.15. Pfizer, Inc.
- 12.15.1. Company details
- 12.15.2. Financial outlook
- 12.15.3. Product summary
- 12.15.4. Recent developments
12.16. Others